¿Metformin to Treat Abdominal Aortic Aneurysms?

Currently, there are no drugs to treat abdominal aortic aneurysms (AAA) outside those indicated as secondary prevention drugs.  

El tratamiento endovascular parece superior a la cirugía en aneurismas rotosWhat this study shows is that diabetic patients treated with metformin had lower AAA incidence than diabetic patients treated without metformin, and even lower incidence than non- diabetic patients, as if metformin per se were a protective factor beyond diabetes. This undoubtedly calls for randomized studies with small AAA and evolution follow up.

 

The present observational and prospective study carried out in Australia included asymptomatic patients with unrepaired AAA of any diameter over 30 mm.


Read also: Several Features Define a Hostile Neck in AAA patients, but Only One Makes the Difference.


Primary end point was the need to repair AAA or AAA related mortality. The association between metformin and AAA related events was assessed using Kaplan Meier analysis and Cox proportional hazard analysis.

 

It included 1080 patients with an initial average diameter of 46.1 mm, followed up for mean 2.5 years.

 

Patients with a diabetes diagnosis in treatment with metformin presented lower AAA related events than non-diabetic patients (adjusted HR 0.63, CI 95% 0.44 to 0.93), while diabetics without metformin did not (adjusted HR 1.15, CI 95% CI 0.83 to 1.59).


Read also: Risk of Colonic Ischemia after Abdominal Aortic Aneurysm Repair.


Findings were similar when looking at patients with ≤50 mm initial diameters.

 

Conclusion

These findings set grounds for a future randomized study to determine the clinical importance of metformin in AAA patients, regardless diameter or the presence or absence of diabetes.

 

Original title: Metformin Prescription is Associated with a Reduction in the Combined Incidence of Surgical Repair and Rupture Related Mortality in Patients with Abdominal Aortic Aneurysm.

Reference: Jonathan Golledge et al. Eur J Vasc Endovasc Surg. 2019 Jan;57(1):94-101.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA/ACC Guideline on the Management of Acute Pulmonary Embolism 2026

The 2026 ACC/AHA guideline for the management of acute pulmonary embolism (PE) introduces a conceptual shift by replacing the traditional “risk-based” classification with an...

FFR Assessment for the Selection of Hypertensive Patients Who Benefit from Renal Stenting

Atherosclerotic renal artery stenosis (ARAS) represents one of the main causes of secondary hypertension (HTN) and is associated with a higher risk of renal...

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Duration of Smoking Cessation and Risk of Amputation After Revascularization in Critical Limb Ischemia

Critical limb ischemia (CLI) is associated with high rates of amputation and mortality. Although smoking cessation improves outcomes after revascularization, the impact of the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...